ClinicalTrials.gg
RecruitingNCT07372040Updated Feb 4, 2026

Add-on Diuretics in Acute Decompensated Heart Failure

A Phase 2 interventional study of empagliflozin and Acetazolamide in Acute Decompensated Heart Failure, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Tanta University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies testing empagliflozin in Heart Failure — 16 open to participants now, 22 under way, 7 of them phase 3. empagliflozin · Heart Failure.

Planned enrollment
35th of 51
66 · median 90
Started
2026
the only one that year
Phase 2
13 of 51
5 open now
Primary completion
2027-02
later than 15 of 21 live
Registered
48th of 51
by date

Among the 51 studies testing empagliflozin in Heart Failure, this one is the 35th largest by planned enrollment, is the only one that started in 2026, is one of 13 in phase 2, reaches primary completion later than 15 of the 21 other live ones, and was the 48th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 51 studies testing empagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing empagliflozin in Heart Failure, or all of them as a file.
02

Study summary

The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.

03

Conditions studied

  • Acute Decompensated Heart Failure

Browse trials for

Keywords

  • Empagliflozin
  • Acetazolamide
  • Metolazone
  • Acute heart failure
  • Add-on therapies to Loop diuretics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients older than 18 years.
  2. Hospital admission with clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload (e.g. edema, ascites confirmed by echography or pleural effusion confirmed by chest X-ray or echography).

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes.
  2. Chronic kidney disease with estimated (eGFR) \<30 mL/min per 1.73 m² or end-stage kidney failure with the need for chronic dialysis treatment.
  3. A systolic blood pressure of less than 90 mmHg.
  4. Cardiogenic shock.
  5. Receipt of acetazolamide maintenance therapy.
  6. Receipt of an SGLT2 inhibitor, thiazide, or thiazide-like diuretic in the 48 hrs before randomization.
  7. Any cause of heart failure leading to decompensation that will need urgent management (eg, acute coronary syndrome, unstable arrhythmias, acute pulmonary embolism).
  8. Pregnant or breastfeeding women.
  9. Moderate to severe anemia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Active comparator
    Empagliflozin group

    will include 22 patients who will receive 10 mg oral empagliflozin administered simultaneously with the first dose of loop diuretics each day for 3 days

    Drug: empagliflozin

  • Active comparator
    Acetazolamide group

    will include 22 patients who will receive 500 mg oral acetazolamide administered simultaneously with the first dose of loop diuretics each day for 3 days

    Drug: Acetazolamide

  • Active comparator
    Metolazone group

    will include 22 patients who will receive 5 mg oral metolazone administered simultaneously with the first dose of loop diuretics each day for 3 days

    Drug: metolazone

Interventions

  • Empagliflozin may augment the natriuretic and aquaretic actions of loop diuretics in patients with acute decompensated heart failure and it does not typically cause electrolyte disturbances and has been shown to improve outcomes in patients with heart failure

  • Acetazolamide can augment the action of loop diuretics in patients with acute decompensated heart failure

  • Metolazone can augment the action of loop diuretics in patients with acute decompensated heart failure

06

What researchers measure

Primary outcomes

  1. The cumulative urine output measured over 3 days

    Time frame: 3 days

Secondary outcomes

  1. - The change in serum level of N-terminal pro-brain natriuretic peptide (NT-proBNP)

    Blood samples will be collected at baseline and after 4 days

    Time frame: 4 days

  2. The change in serum level of Soluble suppression of tumorigenicity 2 (sST2)

    Blood samples will be collected at baseline and after 4 days

    Time frame: 4 days

  3. The change in urinary level of Tissue inhibitor of metalloproteinases-2 (TIMP-2 )

    Urine samples will be collected at baseline and after 3 days

    Time frame: 3 days

  4. The change in urinary level of Insulin-like growth factor-binding protein 7 (IGFBP7)

    Urine samples will be collected at baseline and after 3 days

    Time frame: 3 days

  5. 30-day mortality

    Proportion of patients who die within 30 days of randomization

    Time frame: up to 30 days

  6. Proportion of patients achieving an ADVOR Score ≤ 1 without the need for escalating diuretic strategy

    the treating physician will calculate the congestion score, on a scale from 0 to 10 on the basis of the sum of scores for the degree of edema (0 to 4), pleural effusion (0 to 3), and ascites (0 to 3), with higher scores indicating a worse condition on all scales

    Time frame: 3 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Feb 2027, 12 months later.

Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 12 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Jan 28, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07372040
Lead sponsor
Tanta University
Responsible party
Dalia Abdelhamid Gomaa (assistant lecturer of clinical pharmacy, faculty of pharmacy, Tanta University) — Principal investigator
First posted
Jan 28, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Feb 4, 2026

Study contacts

Dalia A Gomaa, MSc in clinical pharmacy
Contact
dalia_gomaa@pharm.tanta.edu.eg
+20+01063410525
Dalia R El-Afify, Associate professor
Contact
dalia.mohamed1@pharm.tanta.edu.eg
+20+01006831093
Dalia A Gomaa, MSc in clinical pharmacy
principal investigator · Tanta University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Acetazolamide · Metolazone

Start the discussion